Octapharma’s human plasma-derived von Willebrand Factor (VWF)/Factor VIII replacement product Wilate® has been granted expanded approval for prophylaxis by the U.S. Food and Drug Administration (FDA) to include all types of von Willebrand disease (VWD).
Hemophilia Memorial at the National AIDS Memorial Grove in Golden Gate Park opened in September 2017
Researchers in San Francisco, New York, and Oxford describe a new type of hemophilia, arising from a defect in what is now known as factor IX (9). Rosemary Biggs from Oxford, UK, named it Christmas disease, after the first patient, Stephen Christmas.
The foundation hosts an inaugural summit focused on supporting the female and female-identifying population in Atlanta.
In 2017, the foundation introduced the Guías Culturales program. Guías culturales, or cultural guides, are volunteers within the community who speak Spanish and have navigated care for themselves or family members.
In partnership with Mt. Sinai hospital, the foundation publishes clinical findings on oral surgery and dental care in a manual series called Treatment on Hemophilia.
